ST2825, a Small Molecule Inhibitor of MyD88, Suppresses NF-κB Activation and the ROS/NLRP3/Cleaved Caspase-1 Signaling Pathway to Attenuate Lipopolysaccharide-Stimulated Neuroinflammation
Neuroinflammation characterized by microglia activation is the mechanism of the occurrence and development of various central nervous system diseases. ST2825, as a peptide-mimetic MyD88 homodimerization inhibitor, has been identified as crucial molecule with an anti-inflammatory role in several immune cells, especially microglia. The purpose of the study was to investigate the anti-neuroinflammatory effects and the possible mechanism of ST2825. Methods: Lipopolysaccharide (LPS) was used to stimulate neuroinflammation in male BALB/c mice and BV2 microglia cells. The NO level was determined by Griess Reagents. The levels of pro-inflammatory cytokines and chemokines were determined by ELISA. The expressions of inflammatory proteins were determined by real-time PCR and Western blotting analysis. The level of ROS was detected by DCFH-DA staining. Results: In vivo, the improved levels of LPS-induced pro-inflammatory factors, including TNF-α, IL-6, IL-1β, MCP-1 and ICAM-1 in the cortex and hippocampus, were reduced after ST2825 treatment. In vitro, the levels of LPS-induced pro-inflammatory factors, including NO, TNF-α, IL-6, IL-1β, MCP-1, iNOS, COX2 and ROS, were remarkably decreased after ST2825 treatment. Further research found that the mechanism of its anti-neuroinflammatory effects appeared to be associated with inhibition of NF-κB activation and down-regulation of the NLRP3/cleaved caspase-1 signaling pathway. Conclusions: The current findings provide new insights into the activity and molecular mechanism of ST2825 for the treatment of neuroinflammation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
---|---|
Enthalten in: |
Molecules (Basel, Switzerland) - 27(2022), 9 vom: 06. Mai |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhang, Shan-Shan [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 19.05.2022 Date Revised 16.07.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/molecules27092990 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM340892838 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM340892838 | ||
003 | DE-627 | ||
005 | 20231226010518.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/molecules27092990 |2 doi | |
028 | 5 | 2 | |a pubmed24n1136.xml |
035 | |a (DE-627)NLM340892838 | ||
035 | |a (NLM)35566338 | ||
035 | |a (PII)2990 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhang, Shan-Shan |e verfasserin |4 aut | |
245 | 1 | 0 | |a ST2825, a Small Molecule Inhibitor of MyD88, Suppresses NF-κB Activation and the ROS/NLRP3/Cleaved Caspase-1 Signaling Pathway to Attenuate Lipopolysaccharide-Stimulated Neuroinflammation |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.05.2022 | ||
500 | |a Date Revised 16.07.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Neuroinflammation characterized by microglia activation is the mechanism of the occurrence and development of various central nervous system diseases. ST2825, as a peptide-mimetic MyD88 homodimerization inhibitor, has been identified as crucial molecule with an anti-inflammatory role in several immune cells, especially microglia. The purpose of the study was to investigate the anti-neuroinflammatory effects and the possible mechanism of ST2825. Methods: Lipopolysaccharide (LPS) was used to stimulate neuroinflammation in male BALB/c mice and BV2 microglia cells. The NO level was determined by Griess Reagents. The levels of pro-inflammatory cytokines and chemokines were determined by ELISA. The expressions of inflammatory proteins were determined by real-time PCR and Western blotting analysis. The level of ROS was detected by DCFH-DA staining. Results: In vivo, the improved levels of LPS-induced pro-inflammatory factors, including TNF-α, IL-6, IL-1β, MCP-1 and ICAM-1 in the cortex and hippocampus, were reduced after ST2825 treatment. In vitro, the levels of LPS-induced pro-inflammatory factors, including NO, TNF-α, IL-6, IL-1β, MCP-1, iNOS, COX2 and ROS, were remarkably decreased after ST2825 treatment. Further research found that the mechanism of its anti-neuroinflammatory effects appeared to be associated with inhibition of NF-κB activation and down-regulation of the NLRP3/cleaved caspase-1 signaling pathway. Conclusions: The current findings provide new insights into the activity and molecular mechanism of ST2825 for the treatment of neuroinflammation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a BV2 microglia cells | |
650 | 4 | |a ST2825 | |
650 | 4 | |a lipopolysaccharide (LPS) | |
650 | 4 | |a neuroinflammation | |
650 | 7 | |a Heterocyclic Compounds, 2-Ring |2 NLM | |
650 | 7 | |a Interleukin-6 |2 NLM | |
650 | 7 | |a Lipopolysaccharides |2 NLM | |
650 | 7 | |a Myd88 protein, mouse |2 NLM | |
650 | 7 | |a Myeloid Differentiation Factor 88 |2 NLM | |
650 | 7 | |a NF-kappa B |2 NLM | |
650 | 7 | |a NLR Family, Pyrin Domain-Containing 3 Protein |2 NLM | |
650 | 7 | |a Nlrp3 protein, mouse |2 NLM | |
650 | 7 | |a Reactive Oxygen Species |2 NLM | |
650 | 7 | |a ST2825 |2 NLM | |
650 | 7 | |a Spiro Compounds |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
650 | 7 | |a Caspase 1 |2 NLM | |
650 | 7 | |a EC 3.4.22.36 |2 NLM | |
700 | 1 | |a Liu, Man |e verfasserin |4 aut | |
700 | 1 | |a Liu, Dong-Ni |e verfasserin |4 aut | |
700 | 1 | |a Shang, Yu-Fu |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yue-Hua |e verfasserin |4 aut | |
700 | 1 | |a Du, Guan-Hua |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 27(2022), 9 vom: 06. Mai |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
773 | 1 | 8 | |g volume:27 |g year:2022 |g number:9 |g day:06 |g month:05 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules27092990 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 27 |j 2022 |e 9 |b 06 |c 05 |